Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,756 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06718309 | Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC | recruiting | Phase 2 | 40 | First People's Hospital of HangzhouOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT05598528 | Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)(PRECISE) | recruiting | — | 210 | Second Xiangya Hospital of Central South UniversityOTHER |
| 1 |
| Dec 2, 2024 |
| clinicaltrials |
| NCT06626243 | Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers(IMMUNORATS) | recruiting | — | 140 | Scientific Institute San RaffaeleOTHER | 2 | Nov 29, 2024 | clinicaltrials |
| NCT06706713 | Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer | recruiting | Phase 2 | 200 | BeBetter Med IncINDUSTRY | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06648317 | Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions | recruiting | — | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06702826 | Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases | recruiting | Phase 2 | 20 | Rongrong ZhouOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT03193567 | Study of High Efficient Killing Cell Therapy for Advanced NSCLC(HEART) | recruiting | Phase 1 | 15 | Ruijin HospitalOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05979818 | Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer(BRIO) | recruiting | Phase 1 | 6 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06632262 | A Phase 2 Clinical Study of ABSK061 and ABSK043 | recruiting | Phase 2 | 202 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06269211 | Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression(TOPLINE) | recruiting | Phase 2 | 29 | Ruijin HospitalOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06573073 | Evaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M Mutation | recruiting | — | 300 | LifeOS Genomics CorporationINDUSTRY | 1 | Nov 18, 2024 | clinicaltrials |
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | recruiting | Phase 1 / Phase 2 | 316 | Simcha IL-18, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06589778 | A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 124 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06604689 | AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases | recruiting | — | 800 | Fudan UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06388031 | ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI | recruiting | Phase 2 | 27 | Peking Union Medical College HospitalOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06674343 | Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations | recruiting | Phase 3 | 144 | Peking Union Medical College HospitalOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05435248 | Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) | recruiting | Phase 1 / Phase 2 | 354 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06667154 | Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy | recruiting | Phase 2 | 33 | Aline Fusco Fares, MDOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT05468242 | Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy | recruiting | Phase 2 | 116 | Sun Yat-sen UniversityOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT05403554 | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | recruiting | Phase 1 | 70 | Light Chain Bioscience - Novimmune SAINDUSTRY | 2 | Oct 29, 2024 | clinicaltrials |
| NCT05772455 | A Study of XZB-0004 in Patients With Solid Tumors | recruiting | Phase 1 | 128 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT06084806 | Test-retest Evaluation of [18F]F-AraG PET | recruiting | Phase 2 | 10 | CellSight Technologies, Inc.INDUSTRY | 1 | Oct 24, 2024 | clinicaltrials |
| NCT06107374 | Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG | recruiting | Phase 2 | 20 | CellSight Technologies, Inc.INDUSTRY | 1 | Oct 24, 2024 | clinicaltrials |
| NCT04322890 | Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation(PIKACHU) | recruiting | Phase 2 | 6,000 | Hunan Province Tumor HospitalOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT04335292 | Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge(OCELOT) | recruiting | Phase 2 | 200 | Mark VincentOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT05925764 | WSI Based DL for Diagnosing the IASLC Grading System of Lung Adenocarcinoma | recruiting | — | 200 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05501665 | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | recruiting | Phase 1 / Phase 2 | 25 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT05487391 | A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection. | recruiting | Phase 3 | 632 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06538012 | TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06634966 | Segmentectomy for Solid-dominant Lung Cancer | recruiting | Phase 3 | 277 | Fudan UniversityOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06623487 | The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer | recruiting | — | 30 | Ruijin HospitalOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT05557552 | Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer | recruiting | N/A | 56 | Ruijin HospitalOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT05014464 | ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma(ATPase) | recruiting | Phase 2 | 90 | Hunan Province Tumor HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT05991193 | A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer | recruiting | — | 100 | Hunan Province Tumor HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06355609 | Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW(WUKONG-32-RW) | recruiting | Phase 2 | 100 | Hunan Province Tumor HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT04324125 | Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC | recruiting | — | 70 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04324151 | Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC | recruiting | — | 70 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04777175 | A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer | recruiting | — | 186 | Yongchang ZhangOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05295212 | Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB | recruiting | Phase 2 | 120 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05379803 | High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases | recruiting | Phase 2 | 40 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05766800 | Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05830812 | Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma | recruiting | — | 3,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06141226 | Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 148 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06348927 | Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC(WUKONG-32) | recruiting | Phase 2 | 52 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06598839 | Immuno-effect of Tα1 for Stage I NSCLC | recruiting | N/A | 40 | Yousheng MaoOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06523673 | Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer(OPPRESS) | recruiting | Phase 3 | 104 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT06501391 | Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis | recruiting | Phase 2 | 54 | Fudan UniversityOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06180005 | Incidence and Characterization of Drivers Oncogenes in the Population With Lung Cancer Afferents to the Cancer Institute in Aviano (IN.ON.D.)(INOND) | recruiting | — | 700 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT02511288 | LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer(LIBIL) | recruiting | — | 900 | Centre Leon BerardOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT05654454 | A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer | recruiting | Phase 3 | 620 | Mabscale, LLCINDUSTRY | 1 | Aug 16, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 5, 2024source: clinicaltrials